$Alt (260A.JP)$
After going public, the recent stock price has been lackluster (due to losses), but it is expected to turn profitable next fiscal year. There is growth potential in the personal AI sector. It may be a good idea to buy while it's cheap. With a small number of stocks, it may be difficult to buy once it starts to rise (possibility of frequent trading halts).

$Gyre Therapeutics (GYRE.US)$
I have the same Financial Estimates for the top line since the beginning of the year, and if it comes out within the year, I'll be excited 🍺.

$Gyre Therapeutics (GYRE.US)$  
This is a soliloquy about PULM.
When it comes to CBIO, those who bought at the timing of obtaining CVR rights, rather than jumping in during the initial rise (as it was dropping due to the approval gambling fatigue).
Needless to say, I am one of the individuals who jumped into CBIO 😂 So, crossing the approval, I enjoyed the delicious CVR 👍 It might be good either way for the mid to long term.
Certainly, I think I will buy PULM after understanding the details m(__)m.

$Gyre Therapeutics (GYRE.US)$
I struggle to understand why there are sell orders 💧
I want to add but I lack the margin...

$Gyre Therapeutics (GYRE.US)$
It seems that the IND application by the end of the year is after the topline, but it would be better if it can create an efficient and effective two-phase process.
Is the structure of topline -> partnership -> IND ideal?
For now, it is premature to determine Pulma, with details including the rights fixation date undecided.
However, it might be a good timing to turn around. I would like to do it if possible 👀
But if smallpox rages and APDN does not 🚀, I can't do anything... 🥲

$Gyre Therapeutics (GYRE.US)$
Please drop to around 50 dollars soon!
I wonder if the materials will be available soon...